A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

This is an early-phase (first-in-human) study testing a new experimental cancer drug called REGN10597, alone or in combination with cemiplimab (an immunotherapy drug), in adults with advanced solid tumors (cancers that have spread in the body). The study is designed to find the safest and most effective dose. **You may be eligible if...** - You are an adult with a confirmed advanced or metastatic solid tumor cancer - Your cancer has continued to grow despite standard treatments - Depending on the study cohort, you may have specific cancer types including melanoma or kidney cancer that has progressed after immunotherapy - You are able and willing to undergo tumor biopsies **You may NOT be eligible if...** - You have not yet tried standard treatments for your cancer - You are unwilling or unable to have tumor biopsies - Your overall health or organ function does not meet the required thresholds Talk to your doctor to see if this trial is right for you.